Transforming drug discovery with generative AI Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of ...
Kubernetes has become the leading platform for deploying cloud-native applications and microservices, backed by an extensive community and comprehensive feature set for managing distributed systems.
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
The collaboration operates within a fully transparent 𝐝𝐞𝐬𝐢𝐠𝐧–𝐦𝐚𝐤𝐞–𝐭𝐞𝐬𝐭–𝐚𝐧𝐚𝐥𝐲𝐳𝐞 (𝐃𝐌𝐓𝐀) framework that integrates AI-driven molecular design, rapid compound synthesis, and ...
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collaborations VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
You train the model once, but you run it every day. Making sure your model has business context and guardrails to guarantee reliability is more valuable than fussing over LLMs. We’re years into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results